Department of Radiotherapy, Ghent University Hospital, Belgium.
Department of Radiotherapy, Ghent University Hospital, Belgium.
Radiother Oncol. 2014 Jun;111(3):348-53. doi: 10.1016/j.radonc.2014.02.017. Epub 2014 Apr 17.
The anatomical changes, which occur during the radiotherapy treatment for head-and-neck cancer, may compromise the effectiveness of the treatment. This study compares dosimetrical effects of adaptive (ART) and non-adaptive (RT) dose-painted radiotherapy.
For 10 patients, three treatment phases were preceded by a planning PET/CT scan. In ART, phases II and III were planned using PET/CT2 and PET/CT3, respectively. In RT, phases II and III were planned on PET/CT1 and recalculated on PET/CT2 and PET/CT3. Deformable image co-registration was used to sum the dose distributions and to propagate regions-of-interest (ROIs) drawn on PET/CT1 to PET/CT2, PET/CT3 and a last-treatment-day CT-scan.
Re-adjusted dose-painting ART provided higher minimum and lower maximum doses in target ROIs in comparison to RT. On average, ART reduced the parotids' median dose and swallowing structures mean dose by 4.6-7.1% (p>0.05) and 3% (p=0.06), respectively. Dose differences for targets were from -1.6% to 6.6% and for organs-at-risk from -7.1% to 7.1%. Analysis of individual patient data showed large improvements of ROI dose/volume metrics by ART, reaching a 24.4% minimum-dose increase in the elective neck planning target volume and 21.1% median-dose decrease in swallowing structures.
Compared to RT, ART readjusts dose-painting, increases minimum and decreases maximum doses in target volumes and improves dose/volume metrics of organs-at-risk. The results favored the adaptive strategy, but also revealed considerable heterogeneity in patient-specific benefit. Reporting population-average effects underestimates the patient-specific benefits of ART.
头颈部癌症放射治疗过程中的解剖学变化可能会影响治疗效果。本研究比较了自适应(ART)和非自适应(RT)剂量涂药放疗的剂量学效应。
对于 10 名患者,在计划 PET/CT 扫描前进行了三个治疗阶段。在 ART 中,分别使用 PET/CT2 和 PET/CT3 对 II 期和 III 期进行计划。在 RT 中,II 期和 III 期在 PET/CT1 上进行计划,并在 PET/CT2 和 PET/CT3 上重新计算。使用变形图像配准将剂量分布求和,并将在 PET/CT1 上绘制的感兴趣区域(ROI)传播到 PET/CT2、PET/CT3 和最后治疗日的 CT 扫描上。
与 RT 相比,重新调整剂量的 ART 在靶区 ROI 中提供了更高的最小和更低的最大剂量。平均而言,ART 使腮腺的中位数剂量和吞咽结构的平均剂量分别降低了 4.6-7.1%(p>0.05)和 3%(p=0.06)。靶区的剂量差异为-1.6%至 6.6%,危及器官的剂量差异为-7.1%至 7.1%。对个体患者数据的分析表明,ART 显著改善了 ROI 剂量/体积指标,选择性颈部计划靶区的最小剂量增加了 24.4%,吞咽结构的中位数剂量降低了 21.1%。
与 RT 相比,ART 重新调整了剂量涂药,增加了靶区的最小剂量,降低了最大剂量,并改善了危及器官的剂量/体积指标。结果有利于自适应策略,但也显示出患者特异性获益存在相当大的异质性。报告人群平均效应低估了 ART 的患者特异性获益。